GlobeNewswire·Nov 12, 2026, 7:00 AM ET

Parabilis Medicines Reports Third Quarter 2026 Financial Results and Provides Business Updates

Parabilis Medicines presented updated Phase 1/2 data for zolucatetide at ESMO Congress 2026 showing a 72.2% objective response rate at the 32-week landmark & a favorable safety profile in desmoid tumors.
The company reached FDA alignment on dose, regimen, & trial design for the upcoming PEDESTAL Phase 3 registrational trial in desmoid tumors, with initiation expected in the first half of 2027.
A dose-ranging clinical study of zolucatetide for familial adenomatous polyposis (FAP) has been initiated to identify the optimal dose & regimen.
Parabilis entered a clinical collaboration with Revolution Medicines to evaluate zolucatetide combined with zoldonrasib & cetuximab in patients with previously treated RAS G12D mutant microsatellite stable metastatic colorectal cancer.
The company ended the third quarter of 2026 with $1.1 billion in cash, cash equivalents, & marketable securities, expected to fund operations into 2030.
R&D expenses for the quarter were $45.6 million & G&A expenses were $11.3 million, resulting in a net loss of $44.5 million.
The company reported $2.1 million in revenue for the quarter, driven by collaboration agreements.
Craig L. Tendler, M.D., was appointed to the Board of Directors in August 2026.